



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an independent licensee of the Blue Cross and Blue Shield Association

## Zulresso (brexanolone) for the treatment of Post-partum Depression Medical Policy #147 Zulresso (Brexanolone) for the Treatment of Post-partum Depression

<b>This form must be completed and faxed to:</b>	
<b>Medical and Surgical: 1-888-282-0780</b>	<b>Medicare Advantage: 1-800-447-2994</b>
<b>Employee fax line: 888-608-3693</b>	

### CLINICAL DOCUMENTATION

Copies of clinical documentation that supports the medical necessity criteria for Zulresso (Brexanolone) for the Treatment of Post-Partum Depression must be submitted with this form. **If the patient does not meet all the criteria listed below, please submit a letter of medical necessity explaining why an exception is justified.**

Patient Information	
Patient Name:	Today's Date:
BCBSMA ID#:	Date of Treatment:
Patient Telephone Number:	Place of Service:
Date of Birth:	Outpatient <input type="checkbox"/> Inpatient <input type="checkbox"/>

Physician Information	Facility Information
Name:	Name:
Address:	Address:
Phone #:	Phone #:
Fax#:	Fax#:
NPI#:	NPI#:

ALL of the following conditions for Zulresso (Brexanolone) for the treatment of Post-Partum Depression must be met:	
Prescriber is a specialist in the area of patient's diagnosis	<input type="checkbox"/>
Treatment is being delivered in the inpatient setting	<input type="checkbox"/>
Patient meets diagnostic and statistical manual of mental disorders-5 (DSM-5) criteria for major depressive disorder, moderate to severe	<input type="checkbox"/>
Patient was diagnosed during the peripartum period (onset of depressive episode between 3 <sup>rd</sup> trimester and 4 weeks postpartum)	<input type="checkbox"/>
There are no FDA labelled contraindications	<input type="checkbox"/>

**HCPCS CODES****Please check off all the relevant HCPCS codes:**

J3490	Unclassified drugs	<input type="checkbox"/>
J1632	Injection, brexanolone, 1 mg	<input type="checkbox"/>
C9399	Unclassified drugs or biologicals	<input type="checkbox"/>

**Providers should enter the relevant diagnosis code(s) below:**

<b>Code</b>	<b>Description</b>	
F53.0	Postpartum depression	<input type="checkbox"/>

**Providers should enter other relevant code(s) below:**

<b>Code</b>	<b>Description</b>	
XW033F3	Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 3	<input type="checkbox"/>